- Home
- SI vs AUTL Comparison
SI vs AUTL Comparison
Compare SI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SI | AUTL |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.2M | 335.4M |
| IPO Year | 2025 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SI | AUTL |
|---|---|---|
| Price | $21.82 | $1.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $27.00 | $8.75 |
| AVG Volume (30 Days) | 87.4K | ★ 2.2M |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,317,000.00 | $10,120,000.00 |
| Revenue This Year | $46.44 | $98.68 |
| Revenue Next Year | $27.89 | $28.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 49.63 | ★ 496.00 |
| 52 Week Low | $12.00 | $1.18 |
| 52 Week High | $24.60 | $2.58 |
Technical Indicators
Market Signals| Indicator | SI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 65.07 | 31.90 |
| Support Level | $17.83 | $1.18 |
| Resistance Level | $23.08 | $1.71 |
| Average True Range (ATR) | 1.31 | 0.11 |
| MACD | 0.23 | -0.01 |
| Stochastic Oscillator | 83.01 | 38.68 |
Price Performance
Historical ComparisonAbout SI Shoulder Innovations Inc.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System. Geographically, the company operates in United States and are planning to expand.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.